Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Carcinoma, Non-Small-Cell Lung 2Virus Diseases 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Influenza, Human 1Head and Neck Neoplasms 1Ganglioneuroblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1B-cell Malignancies 1

Interventions

zanubrutinib 3tislelizumab 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1Influenza Vaccines 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × B-cell Malignancies × Influenza Vaccines × Clear all
NCT03701438 2020-02-20

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

Gilead Sciences

Terminated
2 enrolled
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡